Ulcerative Colitis - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 421
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: UFE3B9049CBEN
Leaflet:

Download PDF Leaflet

Ulcerative Colitis - Pipeline Review, H2 2016
Ulcerative Colitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 14, 28, 20, 1, 1, 45, 12 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively for Ulcerative Colitis.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Ulcerative Colitis Overview
Therapeutics Development
Ulcerative Colitis - Therapeutics under Development by Companies
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes
Ulcerative Colitis - Pipeline Products Glance
Ulcerative Colitis - Products under Development by Companies
Ulcerative Colitis - Products under Investigation by Universities/Institutes
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Therapeutics Assessment
Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Appendix 405

LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, H2 2016
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2016
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2016
Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2016
Ulcerative Colitis - Pipeline by Abivax S.A., H2 2016
Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd, H2 2016
Ulcerative Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2016
Ulcerative Colitis - Pipeline by Amgen Inc., H2 2016
Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2016
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2016
Ulcerative Colitis - Pipeline by Bionovis SA, H2 2016
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2016
Ulcerative Colitis - Pipeline by Cellceutix Corporation, H2 2016
Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H2 2016
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2016
Ulcerative Colitis - Pipeline by Coherus BioSciences, Inc., H2 2016
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2016
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2016
Ulcerative Colitis - Pipeline by Eli Lilly and Company, H2 2016
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
Ulcerative Colitis - Pipeline by enGene, Inc, H2 2016
Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2016
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2016
Ulcerative Colitis - Pipeline by Galapagos NV, H2 2016
Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2016
Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H2 2016
Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H2 2016
Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H2 2016
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2016
Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2016
Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2016
Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2016
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2016
Ulcerative Colitis - Pipeline by Lycera Corp., H2 2016
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2016
Ulcerative Colitis - Pipeline by Merck & Co., Inc., H2 2016
Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2016
Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H2 2016
Ulcerative Colitis - Pipeline by NeuClone Pty Ltd, H2 2016
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2016
Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H2 2016
Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2016
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2016
Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2016
Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H2 2016
Ulcerative Colitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2016
Ulcerative Colitis - Pipeline by Re-Pharm Limited, H2 2016
Ulcerative Colitis - Pipeline by Rebiotix Inc., H2 2016
Ulcerative Colitis - Pipeline by Sandoz International GmbH, H2 2016
Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H2 2016
Ulcerative Colitis - Pipeline by Shire Plc, H2 2016
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2016
Ulcerative Colitis - Pipeline by Stelic Institute & Co., Inc., H2 2016
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
Ulcerative Colitis - Pipeline by Synlogic Inc, H2 2016
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd., H2 2016
Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H2 2016
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2016
Ulcerative Colitis - Pipeline by TopiVert Ltd, H2 2016
Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H2 2016
Ulcerative Colitis - Pipeline by UCB S.A., H2 2016
Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Ulcerative Colitis - Dormant Projects, H2 2016
Ulcerative Colitis - Dormant Projects (Contd..1), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..2), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..3), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..4), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..5), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..6), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..7), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..8), H2 2016
Ulcerative Colitis - Dormant Projects (Contd..9), H2 2016
Ulcerative Colitis - Discontinued Products, H2 2016
Ulcerative Colitis - Discontinued Products (Contd..1), H2 2016 405

LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, H2 2016
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ulcerative Colitis Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 294 pages

Ask Your Question

Ulcerative Colitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: